Natalizumab for pediatric multiple sclerosis: a systematic review and meta-analysis
Therapeutic Advances in Neurological Disorders
Published online on April 18, 2026
Abstract
Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
Background:Pediatric-onset multiple sclerosis (POMS) is the onset of MS before the age of 18 and accounts for 3%–5% of all multiple sclerosis (MS) cases. Natalizumab (NTZ) is among the higher-efficacy disease-modifying treatments (HETs) in MS and is ...
Background:Pediatric-onset multiple sclerosis (POMS) is the onset of MS before the age of 18 and accounts for 3%–5% of all multiple sclerosis (MS) cases. Natalizumab (NTZ) is among the higher-efficacy disease-modifying treatments (HETs) in MS and is ...